Discuss naloxone with all patients when prescribing opioids

by Pill Pals Customer Service | Jun 25, 2025 | News

To reduce the risk of death from opioid overdose, the U.S. Food and Drug Administration (FDA) is making the following recommendations about the opioid reversal medicine, naloxone:For all patients who are prescribed opioid pain relievers, health care professionals...

Serious heart events, cancer, blood clots for certain JAK inhibitors

by Pill Pals Customer Service | Jun 25, 2025 | News

When FDA first approved Xeljanz (tofacitinib), we required the manufacturer, Pfizer, to conduct a randomized safety clinical trial in patients with rheumatoid arthritis (RA) who were taking methotrexate to evaluate the risk of cardiovascular events, malignancy, and...

Drug Trials Snapshot: ALYFTREK

by Pill Pals Customer Service | Jun 25, 2025 | News

HOW TO USE THIS SNAPSHOTThe information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar...

Update HCP Drug Interactions

by Pill Pals Customer Service | Jun 25, 2025 | News

abiraterone 2D6 moderate inhibitor acyclovir 1A2 weak inhibitor adefovir1 OAT1 substrate alfentanil 3A4 sensitive substrate allopurinol 1A2 weak inhibitor alosetron ...

Warning: infection of genital area with SGLT2 inhibitors for diabetes

by Pill Pals Customer Service | Jun 25, 2025 | News

[8-29-2018] The U.S. Food and Drug Administration (FDA) is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2)...

Early Lyme Disease as Manifested by Erythema Migrans

by Pill Pals Customer Service | Jun 25, 2025 | News

Docket Number: FDA-2022-D-2315 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Early Lyme Disease as Manifested by...